Bio Techne Quick Ratio (TECH) starting from the fourth quarter 2026 to fourth quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Bio techne Corp  (NASDAQ: TECH)

Bio Techne's Quick Ratio

TECH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Bio Techne's Cash & cash equivalent grew by 26.16 % in the Q4 2026 sequentially, faster than Current Liabilities, this led to improvement in Bio Techne's Quick Ratio to 1.62, Quick Ratio remained below Bio techne Corp average.

Within Biotechnology & Pharmaceuticals industry 97 other companies have achieved higher Quick Ratio than Bio Techne in fourth quarter 2026. While Quick Ratio total ranking in the fourth quarter 2026 has deteriorated compared to the prior quarter from 983 to 1577.

Explain Quick Ratio?
How much Cash & cash equivalents TECH´s has?
What are TECH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TECH Quick Ratio (Jun 30 2026)
Q4		 (Mar 31 2026)
Q3		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4
Y / Y Current Liabilities Change -8.64 % -9.41 % 10.33 % 1.7 % 11.32 %
Y / Y Cash & cash equivalent Change 63.22 % 49.16 % 6.1 % -22.7 % 6.1 %
Quick Ratio MRQ 1.62 1.37 0.92 1 0.91
TECH's Total Ranking # 1577 # 983 # 1041 # 1477 # 1547
Seq. Current Liabilities Change 6.8 % -12.84 % 21.66 % -19.33 % 5.89 %
Seq. Cash & cash equivalent Change 26.16 % 29.37 % 11.88 % -10.62 % 15.3 %



Quick Ratio fourth quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 98
Healthcare Sector # 551
Overall Market # 1577


Quick Ratio Statistics
High Average Low
1768.57 58.35 0.8
(Jun 30 2009)   (Mar 31 2017)




Financial Statements
Bio Techne's Current Liabilities $ 164 Millions Visit TECH's Balance sheet
Bio Techne's Cash & cash equivalent $ 265 Millions Visit TECH's Balance sheet
Source of TECH's Sales Visit TECH's Sales by Geography


Cumulative Bio Techne's Quick Ratio

TECH's Quick Ratio for the trailling 12 Months

TECH Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -1.93 % 3.35 % 21.94 % 26.03 % 29.15 %
Y / Y Cash & cash equivalent TTM Growth 21.52 % 7.13 % -4.47 % -12.95 % -1.21 %
Quick Ratio TTM 1.23 1.04 0.91 0.92 0.99
Total Ranking TTM # 3918 # 2201 # 2254 # 3221 # 2825
Seq. Current Liabilities TTM Growth -2.37 % -2.38 % 2.52 % 0.37 % 2.89 %
Seq. Cash & cash equivalent TTM Growth 15.1 % 11.34 % 1.55 % -6.62 % 1.47 %

Quick ratio ranking by company, industry and sector >> Back to TECH Financial Strength Comparisons >> Go to Compare TECH Quick Ratio to its Competitors

On the trailing twelve months basis TECH Cash & cash equivalent soared by 63.22 % in Q4 2026 year on year, while Current Liabilities rose to $164 millions, this led to increase in in Bio Techne's Quick Ratio to 1.23, Quick Ratio remained below TECH average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Bio Techne. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2026 from 2201 to 3918.

Explain Quick Ratio?
How much Cash & cash equivalents TECH´s has?
What are TECH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 142
Healthcare Sector # 890
Within the Market # 3918


trailing twelve months Quick Ratio Statistics
High Average Low
7.56 2.13 0.61
(Jun 30 2011)   (Dec 31 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Dbv Technologies S a   4.37 $ 174.900  Millions$ 40.000  Millions
Metagenomi Therapeutics Inc   4.37 $ 120.700  Millions$ 27.632  Millions
Alpha Cognition Inc.  4.37 $ 41.443  Millions$ 9.493  Millions
Intensity Therapeutics Inc   4.23 $ 9.500  Millions$ 2.245  Millions
Ginkgo Bioworks Holdings Inc   4.15 $ 302.163  Millions$ 72.740  Millions
Dyadic International Inc   4.13 $ 16.047  Millions$ 3.883  Millions
Tenaya Therapeutics Inc   4.11 $ 78.100  Millions$ 19.021  Millions
Vir Biotechnology Inc   4.08 $ 530.522  Millions$ 130.177  Millions
Adaptive Biotechnologies Corporation  3.92 $ 344.255  Millions$ 87.712  Millions
Immunocore Holdings Plc  3.74 $ 880.211  Millions$ 235.198  Millions
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions
Exozymes Inc   3.49 $ 5.653  Millions$ 1.618  Millions
Acumen Pharmaceuticals Inc   3.44 $ 160.954  Millions$ 46.848  Millions
Century Therapeutics inc   3.29 $ 49.642  Millions$ 15.068  Millions
Adma Biologics Inc   3.26 $ 136.020  Millions$ 41.690  Millions
Tscan Therapeutics Inc   3.23 $ 100.156  Millions$ 30.964  Millions
Sutro Biopharma Inc   3.11 $ 164.346  Millions$ 52.898  Millions
Editas Medicine Inc   3.09 $ 211.645  Millions$ 68.434  Millions
Autolus Therapeutics Plc  2.93 $ 201.630  Millions$ 68.790  Millions
Moderna Inc   2.73 $ 6,910.000  Millions$ 2,534.000  Millions
Sana Biotechnology Inc   2.59 $ 320.990  Millions$ 123.752  Millions
Tarsus Pharmaceuticals Inc   2.56 $ 449.690  Millions$ 175.753  Millions
Meiragtx Holdings Plc  2.46 $ 143.166  Millions$ 58.096  Millions
Kodiak Sciences Inc   2.39 $ 125.903  Millions$ 52.770  Millions
Exelixis Inc   2.32 $ 839.385  Millions$ 361.927  Millions
Precision Biosciences Inc  2.19 $ 87.549  Millions$ 39.886  Millions
Novavax inc   2.18 $ 719.340  Millions$ 330.574  Millions
Regenxbio Inc   2.11 $ 174.530  Millions$ 82.621  Millions
Biocardia Inc   2.00 $ 4.117  Millions$ 2.055  Millions
Kymera Therapeutics Inc   1.75 $ 124.477  Millions$ 71.326  Millions

Date modified: 2026-08-29T04:46:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.